奈达铂胸腔灌注治疗恶性胸水的临床观察  

Effect of nedaplatin combined with thoracentesis to control malignant pleural effusion

作　　者：胡传杏子[1] 张志军 

机构地区：[1]华中科技大学附属荆州市中心医院肿瘤科,湖北荆州434020 [2]南京江苏海光应用化学研究所,211112

出　　处：《临床肿瘤学杂志》2009年第4期358-360,共3页Chinese Clinical Oncology

摘　　要：目的:观察胸腔内注射奈达铂(NDP)和顺铂(DDP)治疗恶性胸水的疗效。方法:收集61例晚期各种肿瘤引起的恶性胸水患者,随机分为NDP组和DDP组,两组患者均先排尽胸水,NDP组采用NDP(100mg/次)溶于20～40ml生理盐水中注入胸腔,DDP组用DDP(80mg/次)溶于20～40ml生理盐水中注入胸腔,观察两组胸水治疗的有效率、胸水复发时间,以及患者生存质量变化和中位生存时间。结果:NDP组治疗胸水有效率80.0%,优于DDP组54.5%(P=0.012);呼吸困难缓解程度VAS评分NDP组优于DDP组(P<0.05);中位生存期NDP组413天,DDP组404天,两组无统计学差异。结论:NDP治疗恶性胸水安全有效,其治疗效果优于顺铂。Objective：To investigate the effect of nedaplatin or cisplatin combined with thoracentesis to control malignant pleural effusion（MPE）.Methods：Sixty-one malignant tumors patients were recruited to divide randomly into thoracentesis combined with nedaplatin or thoracentesis combined with cisplatin.Observed the survival period,response rate,recurrent period of MPE,the change of dyspnea was evaluated by VAS scores as well.Results：We found that median follow-up time,median survival period in nedaplatin group showed no statistal deviation with cisplatin group,while effect of control MPE,recurrent period and VAS score after therapy in nedaplain were all superior to cisplatin group.Conclusion：Nedaplatin combined with thoracentesis to cure MPE is safe and useful,the efficacy is superior to cisplatin combined with thoracentesis.

关 键 词：奈达铂 顺铂 恶性胸水 胸腔穿刺 胸腔内化疗 

分 类 号：R730.5[医药卫生—肿瘤]